Literature DB >> 20599350

The seven-year' secondary patency of a fresh arterial allograft in the femorocrural position in a heart transplant recipient.

Pavel Sebesta1, Petr Stádler, Petr Sedivý, Karel Bartík.   

Abstract

Critical limb ischemia in patients with diabetes at the organ complication stage represents a considerable challenge in vascular medicine. Because of the complexity of the disease and the often symmetric involvement of both lower limbs, a discrepancy between suitable vascular conduit availability and the actual requirement can occur: notably, the prevalence of multilevel and diffuse arterial disease often limits the possibilities of endovascular treatment, and, in surgical cases, frequently prohibits the effective use of prosthetic material. In our patient with bilateral critical limb ischemia and previous coronary artery bypass graft followed by cardiac transplantation, only one great saphenous vein remained available. That was used in its entirety to salvage one limb as a sequential femorocrural bypass. A similar surgical procedure with a fresh arterial allograft retrieved from a deceased donor was performed on the other extremity . ABO compatibility as well as the chronic immunosuppressive therapy in a heart transplant recipient may have contributed to the favorable long-term clinical outcome of the allogeneic arterial reconstruction.
Copyright © 2010 Annals of Vascular Surgery Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20599350     DOI: 10.1016/j.avsg.2010.02.049

Source DB:  PubMed          Journal:  Ann Vasc Surg        ISSN: 0890-5096            Impact factor:   1.466


  2 in total

1.  Fresh arterial homograft for bypass in critical limb ischaemia with infection.

Authors:  Stephanie Wayne; Charles Milne; Geoffrey Cox
Journal:  BMJ Case Rep       Date:  2015-05-20

2.  Immunosuppressive protocols with tacrolimus after cryopreserved aortal allotransplantation in rats.

Authors:  Rudolf Spunda; Jan Hruby; Pavel Mericka; Mikulas Mlcek; Ondrej Pecha; Kathrin Splith; Moritz Schmelzle; Felix Krenzien; Jaroslav Lindner; Ivan Matia; Miroslav Spacek
Journal:  PLoS One       Date:  2018-08-09       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.